Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Companyâs platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
髿é·
å瀟ã®åçã¯éå»3幎éã«ãããçå®ã«å¢å ããŠããã幎平åã§79.49%ã®æé·çã瀺ããŠããŸãã
æé·äž
åç€Ÿã¯æé·ãã§ãŒãºã«ãããææ°ã®å¹Žéåçã¯USD 116.67Kã«éããŠããŸãã
é«ãå©çæé·
å瀟ã®çŽå©çã¯æ¥çããªãŒãããŠãããææ°ã®å¹ŽéçŽå©çã¯USD 116.67Kã§ãã
å²é«
åç€Ÿã®ææ°ã®PEã¯-1.29ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé«å€åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯629.79Kæ ªã§ãåååææ¯ã§48.62%æžå°ããŠããŸãã
ãžã§ãŒã ãºã»ã·ã¢ã³ãºãä¿æ
ã¹ã¿ãŒæè³å®¶ãžã§ãŒã ãºã»ã·ã¢ã³ãºã¯æ¬éæã29.96Kæ ªä¿æããŠããŸãã
åžå ޿޻åãäœèª¿
å瀟ãžã®æè³å®¶ã®é¢å¿ã¯äœäžããŠããã20æ¥éã®å£²è²·å転çã¯-0.88ã§ãã